Course of Esophageal Candidiasis and Outcomes of Patients at a Single Center  Patrick Hoversten, Fouad Otaki, David A. Katzka  Clinical Gastroenterology and Hepatology  Volume 17, Issue 1, Pages 200-202.e1 (January 2019) DOI: 10.1016/j.cgh.2018.04.035 Copyright © 2019 AGA Institute Terms and Conditions

Figure 1 (A) Top 8 risk factors in the 3 cohorts. Risk factors were reported as percentages and compared among the 3 group. (B) Distribution of endoscopic findings for all 3 groups. (Bi) Asymptomatic patients. (Bii) Symptomatic patients without cause. (Biii) Symptomatic patients with cause. (C) Flow chart of patient outcomes after treatment or observation after diagnosis of esophageal candidiasis. H2A, histamine 2 receptor antagonist; PPI, proton pump inhibitor. Clinical Gastroenterology and Hepatology 2019 17, 200-202.e1DOI: (10.1016/j.cgh.2018.04.035) Copyright © 2019 AGA Institute Terms and Conditions